Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer

Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer

Epigenetic alterations play a pivotal role in cancer treatment outcomes. Using the methylation array data and The Cancer Genome Atlas (TCGA) dataset, we observed the hypomethylation and upregulation of thiosulfate sulfurtransferase–like domain containing 1 (TSTD1) in patients with breast cancer. We...

Full description

Bibliographic Details
Main Authors:	Muhamad Ansar, Le Thi Anh Thu, Chin-Sheng Hung, Chih-Ming Su, Man-Hsu Huang, Li-Min Liao, Yu-Mei Chung, Ruo-Kai Lin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Oncology
Subjects:	TSTD1 breast cancer DNA methylation hypomethylation chemotherapy hormone therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1004261/full

Similar Items

Low Expression of TSTD2 Serves as a Biomarker for Poor Prognosis in Kidney Renal Clear Cell Carcinoma
by: Tang G, et al.
Published: (2023-04-01)

<i>SMAD3</i> Hypomethylation as a Biomarker for Early Prediction of Colorectal Cancer
by: Muhamad Ansar, et al.
Published: (2020-10-01)

DNA Hypomethylation Is Associated with the Overexpression of INHBA in Upper Tract Urothelial Carcinoma
by: Chien-Chang Kao, et al.
Published: (2022-02-01)

Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer
by: Ruo-Kai Lin, et al.
Published: (2022-06-01)

Eps15 Homology Domain-Containing Protein 3 Hypermethylation as a Prognostic and Predictive Marker for Colorectal Cancer
by: Yu-Han Wang, et al.
Published: (2021-04-01)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
by: De‐hong Wu, et al.
Published: (2020-01-01)

Hypomethylation Causes MIR21 Overexpression in Tumors
by: Jun Lu, et al.
Published: (2020-09-01)

DNA hypomethylation mediates immune response in pan-cancer
by: Chunlong Zhang, et al.
Published: (2023-12-01)

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure
by: Abigail Belasen, et al.
Published: (2020-07-01)

PCGF6/MAX/KDM5D facilitates MAZ/CDK4 axis expression and pRCC progression by hypomethylation of the DNA promoter
by: Meng Zhu, et al.
Published: (2023-03-01)

Automatic Detection of the Circulating Cell-Free Methylated DNA Pattern of <i>GCM2</i>, <i>ITPRIPL1</i> and <i>CCDC181</i> for Detection of Early Breast Cancer and Surgical Treatment Response
by: Sheng-Chao Wang, et al.
Published: (2021-03-01)

Placental Hypomethylation Is More Pronounced in Genomic Loci Devoid of Retroelements
by: Aniruddha Chatterjee, et al.
Published: (2016-07-01)

Consistent DNA Hypomethylations in Prostate Cancer
by: Marcos J. Araúzo-Bravo, et al.
Published: (2022-12-01)

Heparanase Gene Hypomethylation as a Potential Biomarker for Precision Screening of Bladder Cancer
by: Bai-sheng Xu, et al.
Published: (2022-07-01)

VCAN Hypomethylation and Expression as Predictive Biomarkers of Drug Sensitivity in Upper Urinary Tract Urothelial Carcinoma
by: Hao-Lun Luo, et al.
Published: (2023-04-01)

Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma
by: Hao-Lun Luo, et al.
Published: (2021-08-01)

Hypomethylation and Aberrant Expression of the Glioma Pathogenesis-Related 1 Gene in Wilms Tumors
by: Laxmi Chilukamarri, et al.
Published: (2007-11-01)

E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter
by: Kai-Long Liu, et al.
Published: (2022-03-01)

BAGE Hypomethylation Is an Early Event in Colon Transformation and Is Frequent in Histologically Advanced Adenomas
by: Alla Rynditch, et al.
Published: (2009-11-01)

Association of global DNA hypomethylation with clinicopathological variables in colonic tumors of Iraqi patients
by: Ban J Qasim, et al.
Published: (2016-01-01)

Epigenetic Silencing of <i>PTEN</i> and Epi-Transcriptional Silencing of <i>MDM2</i> Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents
by: Paul Lee, et al.
Published: (2022-05-01)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
by: Hussein Awada, et al.
Published: (2023-04-01)

Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
by: Carolina Fazio, et al.
Published: (2018-12-01)

A Hypomethylated population of <it>Brassica rapa</it> for forward and reverse Epi-genetics
by: Amoah Stephen, et al.
Published: (2012-10-01)

Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis
by: Jun Li, et al.
Published: (2022-12-01)

The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia
by: Akiko Urabe, et al.
Published: (2023-02-01)

The role of TET2-mediated ROBO4 hypomethylation in the development of diabetic retinopathy
by: Liangliang Zhao, et al.
Published: (2023-07-01)

Dietary betaine activates hepatic VTGII expression in laying hens associated with hypomethylation of GR gene promoter and enhanced GR expression
by: Nagmeldin A. Omer, et al.
Published: (2018-01-01)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
by: Su-Yeon Bang, et al.
Published: (2023-03-01)

Cross-tissue patterns of DNA hypomethylation reveal genetically distinct histories of cell development
by: Timothy J. Scott, et al.
Published: (2023-10-01)

Ectoine Globally Hypomethylates DNA in Skin Cells and Suppresses Cancer Proliferation
by: Majjid A. Qaria, et al.
Published: (2023-11-01)

Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance
by: Rahul Mishra, et al.
Published: (2023-12-01)

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
by: Chryssoula Kordella, et al.
Published: (2021-03-01)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
by: Alicia Roldán Pérez, et al.
Published: (2022-07-01)

Deregulation of p53 and RB Transcriptional Control Leads to Overexpression of DNA Methyltransferases in Lung Cancer
by: Yen-An Tang, et al.
Published: (2014-06-01)

Dietary taurine supplementation enhances growth and nutrient digestibility in giant grouper Epinephelus lanceolatus fed a diet with soybean meal
by: Yu-Hung Lin, et al.
Published: (2020-11-01)

Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience
by: M. A. Granatkin, et al.
Published: (2023-03-01)

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
by: Xuezhu Xu, et al.
Published: (2023-12-01)

Comparative Analyses of Sperm DNA Methylomes Among Three Commercial Pig Breeds Reveal Vital Hypomethylated Regions Associated With Spermatogenesis and Embryonic Development
by: Siqian Chen, et al.
Published: (2021-10-01)

The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
by: Giovanni Marconi, et al.
Published: (2023-05-01)